Oruka Therapeutics, Inc. ORKA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 23.8×+1.4× | 22.4×+5.4× | 16.9×-10.5× | 27.4×-2.6× | 30×+1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | —— | |
| Valuation | ||||||
| Market capitalization | $2.43B+65.6% | $1.47B+57.7% | $930.43M— | —— | —— | |
| Price / book | 5×+1.9× | 3.1×+1.2× | 1.9×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Oruka Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.